InMed Pharmaceuticals plans 1-for-10 share consolidation
INM•InMed Pharmaceuticals plans a 1-for-10 share consolidation, which would reduce outstanding common shares from 5,493,735 to approximately 549,374. Completion is expected after market close November 4, 2026, subject to shareholder approval of three merger-related proposals.
1. Consolidation timing
InMed Pharmaceuticals plans to complete the share consolidation after market close November 4, 2026, conditional on shareholder approval of three merger-related proposals at that day's meeting. Consolidation-adjusted trading on the Nasdaq Capital Market is expected to begin at market open November 5.
